4.8 Review

Increasing burden of liver disease in patients with HIV infection

期刊

LANCET
卷 377, 期 9772, 页码 1198-1209

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(10)62001-6

关键词

-

资金

  1. Gilead Sciences
  2. Merck Sharpe and Dohme
  3. AIDS Research Trust
  4. Bristol-Myers Squibb
  5. Johnson and Johnson

向作者/读者索取更多资源

Introduction of effective combined antiretroviral therapy has made HIV infection a chronic illness. Substantial reductions in the number of AIDS-related deaths have been accompanied by an increase in liver-related morbidity and mortality due to co-infection with chronic hepatitis B and C viruses. Increases in non-alcoholic fatty liver disease and drug-induced hepatotoxicity, together with development of hepatocellular carcinoma, also potentiate the burden of liver disease in individuals with HIV infection. We provide an overview of the key causes, disease mechanisms of pathogenesis, and recommendations for treatment options including the evolving role of liver transplantation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据